IRBM S.p.A
|
Year Established:
2010 |
|
|
Website:
irbm.com |
|
|
Headquarters:
Pomezia, , IT |
|
|
Company Type:
Mid-Sized Business (10-100M TTM Revenue) |
IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate.
With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing toward clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.
We Make Drugs.
IRBM’s team has a notable track record, developing 3 marketed therapeutics:
ISENTRESS®, the first-in-class HIV integrase inhibitor
Grazoprevir, part of the HCV ZEPATIER® combination therapy
ZEJULA®, a PARP inhibitor for the treatment of ovarian cancer
| Site | Badges | |
|---|---|---|
| IRBM S.p.A Via Pontina Km 30,600 Pomezia, , 00071 Italy | ||
| IRBM S.p.A Via Pontina Km 30,600 Pomezia, , 00071 Italy | ||
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.